Find Out If You Have a Case

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Can you sue over a CTCL diagnosis after Dupixent?

For many patients the honest answer is yes — it turns on a few questions you can answer in two confidential minutes.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Or talk to a person now: (888) 348-2735 — answered 24/7

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

Are people actually suing over Dupixent and CTCL?

They are, and the record is public. The first federal case appeared on a court docket in October 2025. By February 2026 there were enough of them, spread across enough districts, that plaintiffs asked the Judicial Panel on Multidistrict Litigation to gather them in one place. On June 4, 2026 the Panel did exactly that, sending the cases to the District of New Jersey. At least 36 cases were docketed there as of September 15, 2026 — a real but genuinely early-stage litigation, which we track on our MDL 3180 page.

That number matters for an honest reason. It is small. Anyone describing this as a mature, settled, or sure-thing litigation is describing something that does not exist.

What is a failure-to-warn claim, in plain language?

Product-liability law asks a narrow question of a drug maker: did you tell people what you knew, or what you should have known, about the risks of your product? A failure-to-warn claim says the answer was no — that the company had information suggesting a serious risk and did not put it where patients and prescribing doctors would see it, which is the label. That, in outline, is what every Dupixent lawsuit in this consolidation alleges.

Notice what that claim does not require you to believe. It does not require you to believe Dupixent is a bad drug, or that it should be taken off the market, or that it did not help you. Plenty of people in this litigation will tell you the drug changed their life. The allegation is about information: that a risk being discussed in the medical literature, and flagged by the FDA as a potential safety signal it is still evaluating, never made it into the warnings. Whether that allegation is correct is for a court to decide, and no court has.

What would you need to bring a Dupixent claim?

Three things, and they are less exotic than people expect.

A qualifying diagnosis. Cutaneous T-cell lymphoma, or one of the related T-cell and cutaneous lymphoma diagnoses the criteria cover, identified during or after Dupixent use. If your pathology report never uses the letters “CTCL,” that does not settle anything — reports use many different names.

A use history. Roughly when you started, roughly when you stopped if you stopped, and what you were being treated for. There is no minimum length of use in the criteria. Weeks can be enough; nobody is going to disqualify you for a short course.

Records. Pharmacy refill history, prescribing records, the biopsy or pathology report, and treatment notes. Most people do not have these in a folder at home, and they do not need to — records can be requested. If you want to know where you stand before you call, our do I qualify page lays out the criteria exactly as we apply them.

What does it cost to find out?

Nothing, at any stage of asking. The case review is free and confidential. If a case is accepted, representation is on a contingency basis: no fee unless there is a recovery, with court costs and litigation expenses advanced by counsel and repaid from the recovery, and no responsibility for those costs if there is no recovery unless a court directs otherwise. You are never asked for a retainer, a filing fee, or a records fee.

People ask this more often than any other question, and usually apologetically. It is a reasonable question. A specialty biologic is expensive enough without adding legal bills to it.

What does a Dupixent claim not require?

It does not require you to stop taking Dupixent. Current use is a fact in your file, like a start date. No one here will tell you to stop, start, or change any medication — that conversation belongs with your prescriber.

It does not mean suing your doctor. These are claims against the companies that made and sold the drug. Your dermatologist prescribed from a label that, plaintiffs allege, was missing something. Your care relationship is not the target and is not disturbed.

It does not require money up front, or a decision today. Asking a question is not filing a lawsuit, and filing is not a commitment you make on a phone call.

It does not require you to have kept anything. It helps to save evidence like packaging, receipts, and correspondence if you happen to have it, but records requests exist precisely because most people threw the boxes away years ago.

What can nobody tell you yet?

Whether these claims will succeed. No court has ruled on the merits, no settlement exists, no trial has been held, and nobody — at this firm or any other — knows what a Dupixent case is worth or whether it will be worth anything at all. Manufacturers in this posture routinely move to dismiss, challenge the scientific evidence, and argue preemption, and they sometimes prevail. A firm willing to tell you otherwise in August 2026 is telling you something useful about itself.

What is knowable is narrower and more useful: whether your records fit the criteria, what your state’s filing rules are, and what the litigation has actually done so far. Those are the questions a free review answers.

What else do people ask about suing Dupixent’s makers?